How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pancreatic-neuroendocrine-tumor.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pancreatic Neuroendocrine Tumor — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pancreatic Neuroendocrine Tumor (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pancreatic Neuroendocrine Tumor, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Afinitor	everolimus	Novartis	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase mTOR	2009-01-01
Sutent	sunitinib	Pfizer	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Sunitinib Malate	sunitinib-malate	Pfizer	Moderate Risk QT Prolonging Agents	3-phosphoinositide-dependent protein kinase 1	2006-01-01
Sutent	Sunitinib Malate	Pfizer	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Zanosar	STREPTOZOCIN	Teva	Alkylating Drug [EPC]		1982-01-01
Afinitor	Afinitor	Central European Society for Anticancer Drug Research		Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR
Streptozotocin	Streptozotocin	Hoffmann-La Roche

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Pancreatic Neuroendocrine Tumor
Central European Society for Anticancer Drug Research · 1 drug in Pancreatic Neuroendocrine Tumor
Hoffmann-La Roche · 1 drug in Pancreatic Neuroendocrine Tumor
Novartis · 1 drug in Pancreatic Neuroendocrine Tumor
Teva · 1 drug in Pancreatic Neuroendocrine Tumor

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pancreatic Neuroendocrine Tumor:

Cite this brief

Drug Landscape (2026). Pancreatic Neuroendocrine Tumor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pancreatic-neuroendocrine-tumor. Accessed 2026-06-10.

Pancreatic Neuroendocrine Tumor full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing